---
title: "Amgen hits 52-week high during regular trading on Tezspire trial success"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302733458.md"
description: "Amgen rose 2% in intraday trading after Tezspire met primary endpoint in a Phase 3 trial for eosinophilic esophagitis."
datetime: "2026-10-22T14:07:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302733458.md)
  - [en](https://longbridge.com/en/news/302733458.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302733458.md)
generator: "portal-rs"
---

# Amgen hits 52-week high during regular trading on Tezspire trial success

安进 (AMGN.US) 盘中创 52 周新高，现报 446.14 美元，涨 1.78%。

公司近日宣布 Tezspire 在治疗嗜酸性粒细胞性食管炎的三期 CROSSING 临床试验中达成主要终点，实现显著的组织学缓解且疗效持续一年。该药物将在 2026 年欧洲胃肠病学周上公布完整结果。

此外，安进将于 10 月 24 日 ESMO 2026 肿瘤学大会期间举办投资者网络研讨会，管理层将讨论公司肿瘤产品组合及大会展示的相关数据。近期大型制药股在科技股回调背景下获得避险资金青睐，医疗保健板块逆势走强，安进等龙头药企凭借稳健的管线进展和专利延续优势持续吸引机构投资者关注。

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Amgen Inc. $AMGN Shares Acquired by VestGen Advisors LLC](https://longbridge.com/en/news/303720186.md)
- [FDA warns Amgen over cancer drug promotional video](https://longbridge.com/en/news/303273297.md)
- [Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer](https://longbridge.com/en/news/302966836.md)
- [AMGN: DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI](https://longbridge.com/en/news/302970188.md)
- [Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer](https://longbridge.com/en/news/303091953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**